On November 25th, Cassava Sciences announced their experimental Alzheimer’s drug simufilam failed to slow cognitive or functional decline in its 52-week Phase 3 trial….
On September 26th, Cassava Sciences’ founder and former CEO Remi Barbier, as well as former vice president Lindsay Burns agreed to pay the Securities…
Early data presented by Cassava Sciences demonstrates the safety of their Alzheimer’s drug simufilam, which is currently in Phase 3 clinical trials. But in late…
Cassava Sciences revealed positive clinical data from their simufilam trial, a potentially disease-modifying therapy for treating Alzheimer’s. Their preliminary study showed that simufilam significantly…
Wall Street traders seem to have gained a new favorite potential Alzheimer’s treatment as shares of Cassava Science, a small and virtually unknown company,…
This installment of our quarterly Trials Update captures the latest developments in Alzheimer’s and other dementia clinical trials, from January 2025 to present. We’ve…
In November of last year, Cassava Sciences announced their experimental Alzheimer’s drug simufilam failed to slow cognitive or functional decline in its 52-week Phase…
A recent Science investigation found that Eliezer Masliah, one of the world’s leading Alzheimer’s and Parkinson’s researchers, engaged in research misconduct over the course…
This past three months in the Alzheimer’s drug development space have seen a new FDA approval for a symptomatic treatment, a couple failed phase…
In a recent survey, Being Patient put a question to readers: “What is the biggest barrier preventing you from seeking a trial?” The most…
Cassava Sciences’ experimental Alzheimer’s drug simufilam is currently in clinical trials. Meanwhile, the company is experiencing a major shake-up. Its CEO and lead neuroscientist…
Update 17 July, 2024, 3:14 p.m. ET: Cassava Sciences CEO and SVP of neuroscience have resigned from the company following news of federal probes….
Open your medicine cabinet, and you’ll see many examples of the most common type of medication on the market: Small molecule drugs such as…
The monoclonal antibody drugs targeting the brain’s amyloid plaques dominated the news cycle in 2023. Eisai and Biogen’s Leqembi was approved by the FDA…
DEVELOPING STORY, updated 30 October, 2023: In August 2021, the biotechnology company Cassava Sciences — makers of simufilam, an experimental Alzheimer drug currently in…